Sildenafil Aids Ureteric Stone Passage

The phosphodiesterase type 5 (PDE5) inhibitor, sildenafil, improved passage of distal ureteric stones 5–10 mm in diameter.
The phosphodiesterase type 5 (PDE5) inhibitor, sildenafil, improved passage of distal ureteric stones 5–10 mm in diameter.

Sildenafil may be useful as medical expulsive therapy for distal ureteric stones 5–10 mm in diameter, according to research findings published in the Arab Journal of Urology (2016;14:1-6).

Ahmed A. Shokeir, MD, and colleagues at Mansoura University in Mansoura, Egypt, compared sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, with placebo in a randomized, double-blind study that enrolled 100 patients with distal ureteric stones: 50 who received sildenafil 50 mg daily and 50 who received placebo. The groups were comparable with respect to age and stone characteristics. Of the 100 patients, 49 and 47 patients in sildenafil and placebo arms, respectively, were available for analysis. 

Spontaneous stone expulsion occurred in 33 patients (67.3%) in the sildenafil group compared with 19 (40.4%) placebo recipients, a significant difference between the groups. In multivariable analysis, sildenafil treatment was associated with a significant 2.7 times increased likelihood of stone expulsion compared with placebo, according to the researchers. 

Loading links....
You must be a registered member of Renal and Urology News to post a comment.